腋窝淋巴结清扫及即刻淋巴重建后放疗剂量与淋巴水肿风险
这项前瞻性研究纳入23例接受腋窝淋巴结清扫/即刻淋巴重建后区域淋巴结照射的浸润性乳腺癌患者,分析放疗剂量与吻合口及周围区域淋巴水肿的关系。中位随访25.9个月,14例曾符合淋巴水肿标准,末次随访仅4例(17.4%)符合乳腺癌相关淋巴水肿标准。发生淋巴水肿者ILR+2cm体积的平均剂量、V35和V40显著更高,并确定了相应阈值剂量。
要点
- ILR+2cm体积平均剂量≥3074 cGy者淋巴水肿发生率92% vs 30%。
- ILR+2cm体积V35≥56%者淋巴水肿发生率92% vs 22%。
- ILR+2cm体积V40≥50%者淋巴水肿发生率92% vs 30%。
核心结论
- 照射至ILR吻合口部位及周围区域的放疗剂量增加会提高淋巴水肿风险。
研究设计与样本
- 前瞻性研究纳入23例接受腋窝淋巴结清扫/ILR后行RNI的浸润性乳腺癌患者,吻合口以twirl clip标记以便勾画ILR。
- 中位RNI剂量为4000 cGy分16次。
- 淋巴水肿定义为患侧上肢体积增加(优势侧10%、非优势侧7%)或Lymphedema Index增加10点并伴患者报告症状,且发生于放疗结束后6个月以上。
主要发现
- 中位随访25.9个月(四分位距22.8-33.9),14例在超过1个时间点符合淋巴水肿标准,仅4例(17.4%)在末次随访符合BCRL标准。
- 发生淋巴水肿者ILR+2cm体积的平均剂量为4135 cGy vs 1410 cGy(P = .006)。
- 发生淋巴水肿者ILR+2cm体积的V35为89% vs 20%(P = .005)。
- 发生淋巴水肿者ILR+2cm体积的V40为84% vs 17%(P = .012)。
- 上述参数在控制BMI和清扫淋巴结数量后仍显著。
关键数值与推荐
- ILR+2cm体积平均剂量阈值3074 cGy(AUC = 0.86),阈值上下淋巴水肿发生率92% vs 30%,P = .006。
- ILR+2cm体积V35阈值56%(AUC = 0.87),阈值上下淋巴水肿发生率92% vs 22%,P = .001。
- ILR+2cm体积V40阈值50%(AUC = 0.83),阈值上下淋巴水肿发生率92% vs 30%,P = .006。
临床怎么用
- 对接受腋窝淋巴结清扫/ILR后RNI的患者,勾画时关注ILR吻合口及ILR+2cm体积的剂量分布。
- 可参考ILR+2cm体积平均剂量3074 cGy、V35 56%、V40 50%等阈值评估淋巴水肿风险。
- 未来需研究将剂量限制在这些阈值以下能否降低BCRL率并维持疾病控制。
局限性
- 样本量仅23例,随访时间有限。
- 阈值来自单中心前瞻性队列,需外部验证。
- 尚未证实限制剂量低于阈值可降低BCRL率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Regional nodal irradiation (RNI) increases breast cancer-related lymphedema (BCRL) following axillary lymph node dissection despite immediate lymphatic reconstruction (ILR). This study examines the relationship between radiation (RT) dose to the ILR anastomosis and BCRL. METHODS AND MATERIALS: This prospective study included 23 patients with invasive breast cancer who underwent axillary lymph node dissection/ILR followed by RNI. The anastomosis was indicated by a twirl clip, allowing for ILR contouring. The median RNI dose was 4000 cGy in 16 fractions. Lymphedema was defined as an increase in arm volume (10% dominant, 7% nondominant) in the affected extremity or a 10-point increase in Lymphedema Index plus patient-reported symptoms >6 months after RT completion. Dosimetric parameters included mean and maximum doses, V35, V40, Dmin<36.8Gy at the ILR site, ILR + 5 mm, and ILR + 2 cm expansion volumes. RESULTS: Median follow-up was 25.9 months (interquartile range, 22.8-33.9). Fourteen patients met criteria for lymphedema at >1 time point, but only 4 (17.4%) met criteria for BCRL at their last follow-up. Patients who developed lymphedema had higher mean dose (4135 cGy vs 1410 cGy; P = .006), V35 (89% vs 20%; P = .005), and V40 (84% vs 17%; P = .012) at the ILR + 2 cm volume compared with those who did not. These parameters remained significant after controlling for BMI and the number of nodes removed. Threshold doses for lymphedema risk were found for the ILR + 2 cm volume: mean dose, 3074 cGy (AUC = 0.86), with rates of lymphedema above and below the threshold at 92% versus 30%, P = .006; V35, 56% (AUC = 0.87), 92% versus 22%, P = .001; and V40, 50% (AUC = 0.83), 92% versus 30%, P = .006. CONCLUSIONS: Increasing RT doses to the ILR anastomosis site and the surrounding area increased lymphedema risk. Future studies will assess whether limiting the dose below these thresholds can lower BCRL rates while maintaining disease control.
引用
- Spiegel DY, Levey J, Keko M, et al. Radiation Dose and Lymphedema Risk After Immediate Lymphatic Reconstruction and Axillary Lymph Node Dissection. Int J Radiat Oncol Biol Phys. 2026. PMID: 41666961. doi:10.1016/j.ijrobp.2026.01.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。